Ramoplanin: Phase II completed enrollment

GENE completed enrollment of 87 patients in an open-label, U.S. Phase II trial. The study is designed to assess non-inferiority of 200 mg or 400 mg of Ramoplanin twice daily vs. 125 mg of vancomycin 4...